Crinetics Pharmaceuticals Inc美股招股说明书(2026-01-07版)

Prospectus Supplement(To Prospectus dated June21, 2024) 7,620,000 Shares Common Stock We are offering 7,620,000 shares of our common stock in this offering. Our common stock is listed on The Nasdaq Global Select Market under the symbol “CRNX.” On January6, 2026, the last reported sale price of ourcommon stock on The Nasdaq Global Select Market was $45.95 per share. (1)See “Underwriting” for additional information regarding total underwriters’ compensation, including expenses for which we have agreed toreimburse the underwriters. We have granted the underwriters an option for a period of 30 days to purchase up to an additional 1,143,000 shares of our common stock on the sameterms as set forth above. Investing in our common stock involves risks. See “Risk Factors” beginning on pageS-7 of this prospectus supplementand the documents incorporated by reference into this prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passedupon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminaloffense. The underwriters expect to deliver the shares of common stock to purchasers on or about January 8, 2026. Joint Bookrunning Managers J.P. Morgan Piper Sandler Cantor Lead Manager Table of Contents TABLE OF CONTENTS Prospectus Supplement About this Prospectus SupplementProspectus Supplement SummaryRisk FactorsCautionary Note Regarding Forward-Looking StatementsUse of ProceedsDilutionUnderwritingLegal MattersExpertsWhere You Can Find More Information; Information Incorporated by Reference Prospectus About this ProspectusWhere You Can Find More InformationInformation Incorporated by ReferenceThe CompanyRisk FactorsCautionary Note Regarding Forward-Looking StatementsUse of ProceedsDescription of Capital StockDescription of Debt SecuritiesDescription of WarrantsDescription of UnitsGlobal SecuritiesSelling SecurityholdersPlan of DistributionLegal MattersExperts Neither we nor any of the underwriters have authorized anyone to provide information different from that contained in this prospectus supplement.When you make a decision about whether to invest in our common stock, you should not rely upon any information other than the information in thisprospectus supplement. Neither the delivery of this prospectus supplement nor the sale of shares of our common stock means that information containedin this prospectus supplement is correct after the date of this prospectus supplement. This prospectus supplement and the accompanying prospectus arenot an offer to sell or solicitation of an offer to buy shares of our common stock in any circumstances under which the offer or solicitation is unlawful. Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement and the accompanying prospectus dated June21, 2024 are part of a registration statement that we filed with the Securitiesand Exchange Commission (the “SEC”) as a “well-known seasoned issuer,” as defined in Rule 405 under the Securities Act of 1933, as amended(“Securities Act”), utilizing a “shelf” registration process. This prospectus supplement and the accompanying prospectus relate to the offer by us ofshares of our common stock to certain investors. We provide information to you about this offering of shares of our common stock in two separatedocuments that are bound together: (1)this prospectus supplement, which describes the specific details regarding this offering; and (2)theaccompanying prospectus, which provides general information, some of which may not apply to this offering. Generally, when we refer to this“prospectus,” we are referring to both documents combined. If information in this prospectus supplement is inconsistent with the accompanyingprospectus, you should rely on this prospectus supplement. However, if any statement in one of these documents is inconsistent with a statement inanother document having a later date—for example, a document incorporated by reference in this prospectus supplement or the accompanyingprospectus—the statement in the document having the later date modifies or supersedes the earlier statement as our business, financial condition, resultsof operations and prospects may have changed since the earlier dates. You should read this prospectus supplement, the accompanying prospectus, thedocuments and information incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectusthat we have authorized for use in connection with this offering when making your investment decision. You should also read and consider theinformation in the documents we have referred you to under the heading “Where You Can Find More Information; Information Incorporated byReference.” You should rely only on information contained in or incorporated by reference into this prospectus supplement and